Venus Concept Inc. (VERO) 株式分析
ヘルスケアVenus Concept Inc.
$0.31
+$0.01 (+2.64%)
最終更新日: 2026年4月6日
株価推移
価格データがありません
分析
企業概要
Venus Concept Inc. is a medical technology enterprise dedicated to the development, commercialization, and delivery of minimally invasive and non-invasive medical aesthetic and hair restoration technologies alongside related services across the United States and international markets. The company operates within the healthcare sector, specifically focusing on the medical devices industry, a domain characterized by significant regulatory oversight and innovation in patient care solutions. Venus Concept Inc. currently maintains a market capitalization of $578,187 and employs a workforce of 292 individuals to support its operational activities. The company's annual revenue over the trailing twelve months stands at $58.88M, a figure that, when combined with its market cap, indicates a capitalization structure where the enterprise value is disproportionately small relative to its reported sales volume. This valuation profile suggests the market assigns a very low premium to the company's earnings potential at this stage, reflecting either a niche market position or specific challenges in translating revenue into profitability for the investor community.
財務健全性
The company reported a trailing twelve-month revenue of $58.88M, yet it incurred a net loss of $54,614,000, resulting in an EBITDA of $-30,890,000. The substantial gap between the positive revenue figure and the significant negative net income reveals a cost structure where operating expenses and other deductions far exceed gross profits, indicating severe operational inefficiencies or high burn rates in the current fiscal period. Free cash flow for the trailing twelve months was $-12,040,125, which signifies that the company is generating negative cash flow from operations after capital expenditures, thereby limiting its immediate financial flexibility to fund growth without external financing. The gross margin stands at 64.4%, suggesting that the cost of goods sold is relatively well-controlled compared to revenue, while the operating margin is a negative 68.9% and the profit margin is a negative 92.8%, indicating that overhead costs are consuming the vast majority of generated revenue before reaching the bottom line. On the balance sheet, the company holds $4.31M in cash but carries $32.67M in debt, resulting in a debt-to-equity ratio of 1042.31%, which characterizes the financial position as highly leveraged rather than conservative. The current ratio is 0.91, a metric that indicates the company possesses fewer current assets than current liabilities, signaling potential short-term liquidity constraints and an inability to cover immediate obligations without refinancing or asset liquidation. Return on equity is reported at -794.5% and return on assets at -32.4%, metrics that reveal that management is currently destroying value relative to the equity invested and the asset base utilized, rather than generating returns for shareholders.
バリュエーション評価
The trailing twelve-month P/E ratio is listed as N/A due to the company's lack of net income, while the forward P/E is -0.14, a figure that implies the market is pricing in continued earnings contraction or expects significant future losses rather than a path to immediate profitability. The price-to-book ratio is 0.22, indicating that the stock is trading at a significant discount to its book value, suggesting the market values the company's tangible assets at less than 22% of their recorded book amount. The price-to-sales ratio is 0.01, and the EV/EBITDA is -0.95, both of which are alternative valuation metrics that suggest the company is valued extremely cheaply relative to its revenue and enterprise earnings, though the negative figures reflect the underlying financial distress. The 52-week high is $14.50 and the 52-week low is $0.25, meaning the current market price sits in the extreme lower end of this trading range, reflecting a substantial decline from recent highs. The beta value is -0.06, a negative coefficient that indicates the stock's price volatility moves inversely to the broader market or exhibits negligible correlation, which is an unusual characteristic for an equity instrument and suggests a disconnect between general market sentiment and the specific price action of VERO.
Growth & Income
Revenue growth year-over-year is -8.2%, while earnings growth year-over-year is N/A, indicating that the company is shrinking in terms of top-line sales and that profitability is not improving to match any potential revenue stabilization. Since the company is not a dividend payer, with a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute cash to shareholders, meaning the company retains its limited cash reserves or debt proceeds to fund operations rather than paying dividends. The absence of a dividend payout ratio eliminates the sustainability question regarding cash distribution, as the firm currently reinvests all available capital into its core business activities to address the negative growth trajectory. The overall growth and income profile for Venus Concept Inc. is defined by declining revenue, negative earnings, and a complete lack of dividend income, presenting a challenging investment scenario focused entirely on operational turnaround rather than shareholder yield or consistent growth.
同業他社比較
Venus Concept Inc. (VERO) は医療機器業界で事業を展開しています。時価総額による最も近い同業他社との比較は以下の通りです:
| 企業名 | ティッカー | 時価総額 | PER |
|---|---|---|---|
| Venus Concept Inc. | VERO | $578,187 | N/A |
| Abbott Laboratories | ABT | $150.96B | 24.3 |
| Stryker Corporation | SYK | $119.99B | 36.2 |
| Medtronic plc | MDT | $99.63B | 21.7 |
医療機器業界の平均PERは60.2倍です。Venus Concept Inc.のPERはN/Aです。
この分析はAIによって生成されたものであり、情報提供のみを目的としています。投資アドバイスではありません。データは遅延または不正確な場合があります。投資判断を行う前に、必ずご自身で調査を行い、資格を持つファイナンシャルアドバイザーにご相談ください。
関連する医療機器銘柄
Abbott Laboratories
$150.96B
SYKStryker Corporation
$119.99B
MDTMedtronic plc
$99.63B
BSXBoston Scientific Corporation
$85.67B
EWEdwards Lifesciences Corporation
$50.41B
GEHCGE HealthCare Technologies Inc.
$29.19B
ヘルスケアの人気銘柄
Eli Lilly and Company
$949.47B
JNJJohnson & Johnson
$554.09B
ABBVAbbVie Inc.
$376.54B
UNHUnitedHealth Group Incorporated
$342.24B
MRKMerck & Co., Inc.
$302.33B
Venus Concept Inc.について
Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, a portable and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF combined with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, flanks, back, and thighs in individuals with a body mass index BMI of 30 or less; Venus Glow, a Motorized dermabrasion device used to improve skin appearance; and NeoGraft, a hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada.
企業説明は英語で表示されています。
ウェブサイトを見る →主要指標
- 時価総額
- $578,187
- PER
- N/A
- 52週高値
- $12.93
- 52週安値
- $0.25
- 平均出来高
- 6.41M
- ベータ
- -0.06
データはYahoo Financeよりyfinance経由で提供。毎日更新。
企業情報
- 業種
- 医療機器
- 取引所
- PNK
- 国
- Canada
- 従業員数
- 292